- Home
- MYGN vs HONE Comparison
MYGN vs HONE Comparison
Compare MYGN & HONE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- HONE
- Stock Information
- Founded
- MYGN 1991
- HONE 1917
- Country
- MYGN United States
- HONE United States
- Employees
- MYGN N/A
- HONE N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- HONE Major Banks
- Sector
- MYGN Health Care
- HONE Finance
- Exchange
- MYGN Nasdaq
- HONE Nasdaq
- Market Cap
- MYGN 642.0M
- HONE 547.7M
- IPO Year
- MYGN 1995
- HONE 2016
- Fundamental
- Price
- MYGN $8.33
- HONE $13.35
- Analyst Decision
- MYGN Hold
- HONE Buy
- Analyst Count
- MYGN 13
- HONE 3
- Target Price
- MYGN $13.50
- HONE $14.50
- AVG Volume (30 Days)
- MYGN 959.5K
- HONE 623.7K
- Earning Date
- MYGN 11-04-2025
- HONE 10-24-2025
- Dividend Yield
- MYGN N/A
- HONE 2.70%
- EPS Growth
- MYGN N/A
- HONE 71.76
- EPS
- MYGN N/A
- HONE 0.65
- Revenue
- MYGN $832,900,000.00
- HONE $164,819,000.00
- Revenue This Year
- MYGN $0.06
- HONE N/A
- Revenue Next Year
- MYGN $5.68
- HONE $14.24
- P/E Ratio
- MYGN N/A
- HONE $20.50
- Revenue Growth
- MYGN 3.83
- HONE N/A
- 52 Week Low
- MYGN $3.76
- HONE $8.89
- 52 Week High
- MYGN $22.92
- HONE $14.29
- Technical
- Relative Strength Index (RSI)
- MYGN 64.16
- HONE 46.57
- Support Level
- MYGN $7.68
- HONE $13.12
- Resistance Level
- MYGN $8.25
- HONE $14.06
- Average True Range (ATR)
- MYGN 0.38
- HONE 0.42
- MACD
- MYGN -0.01
- HONE -0.08
- Stochastic Oscillator
- MYGN 78.80
- HONE 38.46
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About HONE HarborOne Bancorp Inc.
HarborOne Bancorp Inc is a bank holding company. The company is engaged in providing financial services like accepting deposits, lending loans, online and mobile banking, cash management, credit cards, money market accounts, and wealth management. The Company has two reportable segments: HarborOne Bank and HarborOne Mortgage. The bank provides financial services to individuals and businesses online and through its full-service branches located in Massachusetts and Rhode Island, one limited-service branch, and a commercial lending office in Boston, Massachusetts, and Providence, Rhode Island.